Capital Research Global Investors
RYTM icon

Capital Research Global Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Capital Research Global Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97M Buy
1,115,460
+130,374
+13% +$12.7M 0.02% 314
2025
Q4 		$105M Buy
985,086
+386,839
+65% +$41M 0.02% 299
2025
Q3 		$60.4M Buy
+598,247
New +$55.5M 0.01% 337

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Capital Research Global Investors's RYTM Position: Q1 2026 in Review

Capital Research Global Investors increased its Rhythm Pharmaceuticals (RYTM) stake by 13% in Q1 2026, buying an estimated $12.7M and bringing the position to 1,115,460 shares worth $97M. The position accounts for 0.02% of the portfolio, ranked #314.

Capital Research Global Investors first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. The position peaked at $105M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Capital Research Global Investors held 1,115,460 shares of Rhythm Pharmaceuticals worth $97M as of Q1 2026.
  • Capital Research Global Investors bought 130,374 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
  • Rhythm Pharmaceuticals made up 0.02% of Capital Research Global Investors's portfolio in Q1 2026, its #314 holding.
  • Capital Research Global Investors first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Capital Research Global Investors's Rhythm Pharmaceuticals position peaked at $105M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.